Progress in Dermatology and Venereology in 2023 as Reflected in the Journal of the European Academy of Dermatology and Venereology

    Johannes Ring
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This study found that among melanoma patients in a real-world setting, adjuvant anti-PD-1 antibodies and BRAF/MEK inhibitors were associated with a recurrence-free survival of 78.1% and 86.5% respectively after 12 months.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results